Business
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathologyFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular DegenerationCash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on...
About this update from Inmed Pharmaceuticals Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":327,"olType":false},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC ("BayMedica").","length":571,"tagName":"p"},{"type":"text","content":"The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2025, are available at www.inmedpharma.com and at www.sedar.com.","length":164,"tagName":"p"},{"type":"text","content":"Eric A. Adams, InMed Chief Executive Officer, commented, "Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901's potential as a small-molecule drug candidate that addresses Alzheimer's disease across several interrelated biological pathways rather than relying on a single mechanism. We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer's pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification."","length":874,"tagName":"p"},{"type...